BrainsWay Deep TMS vs EXOMIND

Independent side-by-side comparison with pricing, specs, and clinical evidence.

Why This Comparison Matters

BrainsWay Deep TMS and EXOMIND sit in the same tms devices category but take different approaches. BrainsWay Deep TMS (BrainsWay) uses Deep TMS (H-Coil Technology) for deeper brain stimulation while EXOMIND (BTL Industries) uses ExoTMS (patented external TMS with proprietary coil design). Both received FDA clearance (2013 and 2024 respectively) and both are actively sold in the US market. The decision between them is rarely about which is objectively better. It's about which fits your specific practice.

Physicians end up comparing these two devices when they're shopping in the $100,000-$200,000 to $100,000-$200,000 price range and want a category leader. Both devices are commonly recommended by sales reps from competing manufacturers, which means physicians often hear inflated claims about one and dismissive claims about the other. This comparison strips out the marketing and looks at pricing, mechanism, evidence, and practice fit side by side.

Side-by-Side Specifications

BrainsWay Deep TMS EXOMIND
Manufacturer BrainsWay BTL Industries
Technology Deep TMS (H-Coil Technology) for deeper brain stimulation ExoTMS (patented external TMS with proprietary coil design)
Price (New) $100,000-$200,000 $100,000-$200,000
Price (Used) $50,000-$120,000 Limited secondary market (too new)
Treatment Time 20 minutes per session Under 30 minutes per session
Sessions 20-30 sessions 6 sessions (significantly fewer than competitors)
Per Session $300-$500 (insurance reimbursable) TBD (emerging pricing)
Annual Consumables Minimal (helmet-based, no disposable coils) TBD
Annual Maintenance $5,000-$10,000 TBD
FDA Cleared Yes (2013) Yes (2024)

Technology

BrainsWay Deep TMS

Technology: Deep TMS (H-Coil Technology) for deeper brain stimulation. Deepest TMS stimulation available (6cm vs 2cm). FDA-cleared for depression, OCD, and smoking cessation. Helmet design means no manual positioning required.

EXOMIND

Technology: ExoTMS (patented external TMS with proprietary coil design). FDA-cleared for depression in just 6 sessions (vs 20-36 for competitors). Also cleared in Canada/EU for anxiety, OCD, and binge eating.

Pricing

BrainsWay Deep TMS

New: $100,000-$200,000. Used: $50,000-$120,000. Per session: $300-$500 (insurance reimbursable). Annual consumables: Minimal (helmet-based, no disposable coils). Annual maintenance: $5,000-$10,000.

EXOMIND

New: $100,000-$200,000. Used: Limited secondary market (too new). Per session: TBD (emerging pricing). Annual consumables: TBD. Annual maintenance: TBD.

Clinical Evidence

BrainsWay Deep TMS

Strong. Multiple RCTs for depression and OCD. Unique evidence for smoking cessation indication.

EXOMIND

Emerging. FDA clearance data is available. Full peer-reviewed evidence base still developing.

Treatment Experience

BrainsWay Deep TMS

20 minutes per session per session. Recommended protocol: 20-30 sessions. Treatment areas: Prefrontal cortex (deeper penetration than standard TMS). Patients typically tolerate this platform well when operated by trained clinicians.

EXOMIND

Under 30 minutes per session per session. Recommended protocol: 6 sessions (significantly fewer than competitors). Treatment areas: Dorsolateral prefrontal cortex. Patient experience varies by operator training and settings.

Practice Fit

BrainsWay Deep TMS

Psychiatrists who want the deepest stimulation available and value the expanded indication set (OCD, smoking cessation). Practices serving treatment-resistant patients where standard TMS depth may be insufficient.

EXOMIND

Psychiatrists or multi-specialty practices already in the BTL ecosystem. Early adopters willing to bet on the 6-session protocol advantage.

Pros and Cons

BrainsWay Deep TMS Pros

  • Deepest brain stimulation in TMS category (6cm with H-coil)
  • FDA-cleared for 3 indications (depression, OCD, smoking cessation)
  • Helmet design eliminates operator positioning variability
  • 20-minute sessions (shorter than NeuroStar standard)

BrainsWay Deep TMS Cons

  • Higher upfront cost than NeuroStar
  • Smaller installed base means less peer reference data
  • Helmet design can be uncomfortable for some patients

EXOMIND Pros

  • Only 6 sessions required (vs 20-36 for NeuroStar/BrainsWay)
  • BTL's sales and support infrastructure
  • Potential for anxiety, OCD, binge eating clearances in US
  • Cross-sell path for existing BTL aesthetic practices

EXOMIND Cons

  • Brand new to market (2024 FDA clearance)
  • Limited published clinical evidence vs established competitors
  • Pricing not yet stabilized

The Verdict

Choose BrainsWay Deep TMS if your practice prioritizes BrainsWay's ecosystem, brand recognition, or specific clinical advantages. Psychiatrists who want the deepest stimulation available and value the expanded indication set (OCD, smoking cessation). Practices serving treatment-resistant patients where standard TMS depth may be insufficient. The pros that matter most: Deepest brain stimulation in TMS category (6cm with H-coil); FDA-cleared for 3 indications (depression, OCD, smoking cessation). The biggest tradeoff to accept: Higher upfront cost than NeuroStar.

Choose EXOMIND if BTL Industries's positioning fits better. Psychiatrists or multi-specialty practices already in the BTL ecosystem. Early adopters willing to bet on the 6-session protocol advantage. The pros that matter most: Only 6 sessions required (vs 20-36 for NeuroStar/BrainsWay); BTL's sales and support infrastructure. The biggest tradeoff to accept: Brand new to market (2024 FDA clearance).

For a practice with limited capital that needs maximum flexibility, used pricing tilts the math. BrainsWay Deep TMS used units run $50,000-$120,000; EXOMIND used units run Limited secondary market (too new). For practices with strong patient flow already, the device that integrates with your existing platforms is usually the right answer even if its standalone specs are slightly weaker. For practices building a category from scratch, brand recognition and patient demand matter more than raw clinical specs. Look at which device patients are already asking for in your market before signing a contract.

Frequently Asked Questions

Which is more expensive, BrainsWay Deep TMS or EXOMIND?

BrainsWay Deep TMS runs $100,000-$200,000 new and $50,000-$120,000 used. EXOMIND runs $100,000-$200,000 new and Limited secondary market (too new) used. Per-session pricing is $300-$500 (insurance reimbursable) for BrainsWay Deep TMS and TBD (emerging pricing) for EXOMIND. Annual operating costs (consumables plus maintenance) typically run 5-15% of purchase price for both devices. The right financial comparison includes total cost of ownership over 5 years, not just sticker price.

Which has better clinical evidence, BrainsWay Deep TMS or EXOMIND?

BrainsWay Deep TMS clinical evidence: Strong. Multiple RCTs for depression and OCD. Unique evidence for smoking cessation indication. EXOMIND clinical evidence: Emerging. FDA clearance data is available. Full peer-reviewed evidence base still developing. Evidence quality is not just about study count. Look at sample sizes, blinded evaluators, independence from manufacturer funding, and outcome durability. Older devices in the same category usually have stronger evidence simply because they've been studied longer.

Is BrainsWay Deep TMS or EXOMIND more popular in psychiatry practices?

Both BrainsWay Deep TMS and EXOMIND are commonly used in psychiatry, neurology practices. Market share in any given category shifts year to year. BrainsWay and BTL Industries both maintain active sales forces in the US. Ask other physicians in your specialty which platform they're using and why. Peer references in your local market matter more than national market share data.

Are there safety concerns with BrainsWay Deep TMS or EXOMIND?

Both devices are FDA cleared and have established safety profiles. BrainsWay Deep TMS has these documented concerns: Higher upfront cost than NeuroStar. EXOMIND has: Brand new to market (2024 FDA clearance). Physicians should monitor FDA MAUDE reports for both devices before purchase. Adverse event trends matter because they signal problems that may not appear in marketing materials. Any device with a sudden spike in MAUDE filings deserves closer scrutiny.

Can I use BrainsWay Deep TMS and EXOMIND in the same practice?

Some practices run both devices, especially when they target different patient segments or treatment areas. The downside is duplicated training, parallel consumable inventories, and potential cannibalization between platforms. The upside is broader marketing claims and the ability to switch patients between platforms if one doesn't deliver expected results. Most practices choose one and commit to mastering it rather than splitting volume.

What's the resale value comparison between BrainsWay Deep TMS and EXOMIND?

Used BrainsWay Deep TMS sells for $50,000-$120,000 on the secondary market. Used EXOMIND sells for Limited secondary market (too new). Resale values depend on age, software version, applicator condition, and remaining warranty. Devices with strong installed bases hold value better. Devices with active safety signals or declining manufacturer financial health depreciate faster. Resale value should be a factor in any device purchase, especially if practice plans might change in 3-5 years.